

FOR IMMEDIATE RELEASE:

Cerestim incorporates, targeting transcranial stimulation and related technologies and markets.

London, UK – April 3rd, 2014 – Cerestim Ltd has incorporated as a UK limited company to commercialise research into transcranial stimulation and related technologies.

Transcranial stimulation is the therapeutic treatment of brain conditions using either low level electrical waveforms typically less than 2mA (tDCS and tACS), or magnetic fields less than 2 tesla (TMS). It is the subject of more than 88,000 research papers and scholarly articles and 750 lab trials.

Co-founder Nir Grossman said "this is a very promising area of neuroscience which has not yet made the journey from lab to clinic. Currently, there are rapid advances in high computation and resolution neuroimaging; new micro and nanoscale sensor and nerve modulation interfaces; and advances in low power but very fast digital signal processing electronics. These advances make neurotechnology the science with the greatest potential for major scientific discoveries and therefore both improved health outcomes."

Co-founder Alan Ambrose said "there are a number of scientific, engineering and design challenges that need to be overcome to create a successful product. We are confident that we are building one of the very best teams to address those challenges."

Cerestim has informal links with a number of academic institutions and commercial enterprises and plans to leverage and formalise those over the coming year. It believes it has some world-beating in-house IP which it is looking to file in 2014.

Contact:

Alan Ambrose
alan.ambrose@cerestim.com

###